

**PCR-/NAT *Mycoplasma pneumoniae*
 (RV 541) November 2024**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

Proben Nr.	Erwartet / expected		Probenzusammensetzung / Sample composition
541A 241015 01	++	61	<i>Mycoplasma pneumoniae</i> (~ 1x10 ⁵ genome copies/mL)
541A 241015 02	+++	61	<i>Mycoplasma pneumoniae</i> (~ 1x10 ⁶ genome copies/mL)
541A 241015 03	+	61	<i>Mycoplasma pneumoniae</i> (~ 1x10 ⁴ genome copies/mL)
541A 241015 04	∅	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n</i> = 144	Proben Nr. (Sample no.)					Inhibition			
	01	02	03	04		01	02	03	04
Befund <i>Result</i>									
Positiv	140	144	117	0	n.d.	1	1	1	1
Negativ	4	0	26	144	nein <i>no</i>	143	143	143	143
Fraglich <i>Questionable</i>	0	0	1	0	ja <i>yes</i>	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number)	NAT richtig positiv <i>True positive results</i>						NAT richtig negativ	
	02		03		04		01	
	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%
AID CAP bacteria (n= 4)	4	100	1	25	4	100	3	75
ARGENE C.pn / M.pn r-gene (n= 5)	5	100	5	100	5	100	5	100
Amplex eazyplex PneumoBug exp. (n= 3)	3	100	1	33	3	100	2	67
AmpliGnost M. pneumoniae (n= 4)	4	100	3§	75	4	100	4	100
AusDiagnostics Resp. Pathogens 24-well (n= 1)	1	100	1	100	1	100	1	100
BioGx auf BD Max (n= 8)	8	100	8	100	8	100	8	100
FILMARRAY Resp. Panel 2.1 plus (n= 3)	3	100	2	67	3	100	2	67

Biologio ReadyMax b-CAP Assay (n= 1)	1	100	1	100	1	100	1	100
GeneProof M. pneumoniae (n= 6)	6	100	4	67	6	100	6	100
Luminex MagPix Resp. Pathogen (n= 5)	5	100	4	80	5	100	4	80
Luminex NxTAG Resp. Pathogen + SARS-CoV-2 (n= 1)	1	100	1	100	1	100	1	100
ampliCube Resp. panel 1.1 /1.1LC (n= 14)	14	100	12	86	14	100	14	100
Alethia Mycoplasma direct (n= 3)	3	100	0	0	3	100	3	100
QIAstat-Dx Resp. Sars CoV-2 panel (n= 2)	2	100	2	100	2	100	2	100
Sacace M.pn./C.pn. Real-TM (n= 1)	1	100	1	100	1	100	1	100
Sartorius Microsart ATMP Myc. (n= 2)	2	100	1	50	2	100	2	100
Seegene Allplex Pneumobacter (n= 8)	8	100	6	75	8	100	8	100
Seegene Allplex Resp. Panel 4 (n= 17)	17	100	16	94	17	100	17	100
LightMix M. pneumoniae (n= 10)	10	100	9	90	10	100	10	100
RIDAGENE CAP Bac (n= 9)	9	100	6	67	9	100	9	100
In house PCR assay (n= 21)	21	100	20	95	21	100	21	100
Other commercial tests (n= 16)	16	100	13	81	16	100	16	100

The following tests are listed under "Other commercial tests": QIAGEN QIAstat-Dx ME Panel (3x), CerTest VIASURE C. pneumonia, M. pneumonia and L. pneumophila Real Time PCR Detection Kit (CML172) (2x), ELITechGroup Respiratory Bacterial ELITe MGB Panel (2x), Roche UC-TIB-Respi-Bac2 (L.pn, C.pn, M.pn) (2x), Anatolia Geneworks Bosphore M. pneumoniae Detection Kit v1 (1x), Ingenetix BactoReal M. pneumoniae (1x), Macro & Micro-Test Rt-Pcr Kit For Detecting Six Kinds Of Respiratory Pathogens (1x), PathoFinder RespiFinder 2Smart (1x) and r-Biopharm RIDAUNITY CAP Bac RUO (1x).

§ Fraglich Due to reporting questionable results, the number of true results has been reduced.